Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone

Tomoaki Takao; Kentaro Tanaka; Yoshimasa Shiraishi; keiichi ota; Yasuto Yoneshima; Eiji Iwama; Isamu Okamoto

doi:10.1016/j.cllc.2021.03.003

Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone

Tomoaki Takao, Kentaro Tanaka, Yoshimasa Shiraishi, keiichi ota, Yasuto Yoneshima, Eiji Iwama, Isamu Okamoto

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

• We describe a case of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a patient treated with osimertinib. • A 75-year-old woman was diagnosed with stage IV lung adenocarcinoma (T2aN0M1a) harboring an exon-19 deletion of epidermal growth factor receptor and was treated with osimertinib. After 14 days, she developed headache and nausea. The laboratory results fulfilled the diagnostic criteria of SIADH. • Osimertinib was discontinued, and the patient was treated with sodium intake and fluid restriction. The serum sodium level improved within 1 week. • After discontinuation of osimertinib treatment, the patient was started on gefitinib. She has been able to continue gefitinib treatment without development of hyponatremia.

Original language	English
Pages (from-to)	e784-e785
Journal	Clinical Lung Cancer
Volume	22
Issue number	5
DOIs	https://doi.org/10.1016/j.cllc.2021.03.003
Publication status	Published - Sept 2021

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cllc.2021.03.003

Cite this

@article{635e0cc28a27421aadcb8bb76796ed0b,

title = "Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone",

abstract = " • We describe a case of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a patient treated with osimertinib. • A 75-year-old woman was diagnosed with stage IV lung adenocarcinoma (T2aN0M1a) harboring an exon-19 deletion of epidermal growth factor receptor and was treated with osimertinib. After 14 days, she developed headache and nausea. The laboratory results fulfilled the diagnostic criteria of SIADH. • Osimertinib was discontinued, and the patient was treated with sodium intake and fluid restriction. The serum sodium level improved within 1 week. • After discontinuation of osimertinib treatment, the patient was started on gefitinib. She has been able to continue gefitinib treatment without development of hyponatremia.",

author = "Tomoaki Takao and Kentaro Tanaka and Yoshimasa Shiraishi and keiichi ota and Yasuto Yoneshima and Eiji Iwama and Isamu Okamoto",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = sep,

doi = "10.1016/j.cllc.2021.03.003",

language = "English",

volume = "22",

pages = "e784--e785",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone

AU - Takao, Tomoaki

AU - Tanaka, Kentaro

AU - Shiraishi, Yoshimasa

AU - ota, keiichi

AU - Yoneshima, Yasuto

AU - Iwama, Eiji

AU - Okamoto, Isamu

PY - 2021/9

Y1 - 2021/9

N2 - • We describe a case of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a patient treated with osimertinib. • A 75-year-old woman was diagnosed with stage IV lung adenocarcinoma (T2aN0M1a) harboring an exon-19 deletion of epidermal growth factor receptor and was treated with osimertinib. After 14 days, she developed headache and nausea. The laboratory results fulfilled the diagnostic criteria of SIADH. • Osimertinib was discontinued, and the patient was treated with sodium intake and fluid restriction. The serum sodium level improved within 1 week. • After discontinuation of osimertinib treatment, the patient was started on gefitinib. She has been able to continue gefitinib treatment without development of hyponatremia.

AB - • We describe a case of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a patient treated with osimertinib. • A 75-year-old woman was diagnosed with stage IV lung adenocarcinoma (T2aN0M1a) harboring an exon-19 deletion of epidermal growth factor receptor and was treated with osimertinib. After 14 days, she developed headache and nausea. The laboratory results fulfilled the diagnostic criteria of SIADH. • Osimertinib was discontinued, and the patient was treated with sodium intake and fluid restriction. The serum sodium level improved within 1 week. • After discontinuation of osimertinib treatment, the patient was started on gefitinib. She has been able to continue gefitinib treatment without development of hyponatremia.

UR - http://www.scopus.com/inward/record.url?scp=85104062896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104062896&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2021.03.003

DO - 10.1016/j.cllc.2021.03.003

M3 - Article

C2 - 33839042

AN - SCOPUS:85104062896

SN - 1525-7304

VL - 22

SP - e784-e785

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 5

ER -

Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this